PRTCY — PureTech Health plc
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1782999 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-09-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 637,278,000 | 121,275,000 | 257,789,000 |
| Dec 2025 | — | — | — | — | 534,710,000 | 252,470,000 | 229,034,000 |
| Jun 2025 | — | — | — | — | 553,242,000 | 260,604,000 | 184,217,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,231,000
Inventory
—
Receivables
—
ST Investments
$24,829,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,365,000
EBITDA
$-101,248,000
Free Cash Flow
$-94,309,000
Enterprise Value
$330,850,080
Total Cash
$231,518,000
Total Debt
$222,726,000
Shares Out
24,341,819
Trailing EPS
$0.00
Book Value
$15.87
ROE
0.4%
ROA
-10.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,659,000 | -98,525,000 | -109,739,000 | 534,710,000 | 229,034,000 | 312,073,000 | -85,131,000 |
| Dec 2024 | 4,315,000 | -136,095,000 | 53,510,000 | 602,635,000 | 194,702,000 | 414,707,000 | -134,369,000 |
| Dec 2023 | 750,000 | -146,201,000 | -65,697,000 | 693,973,000 | 235,742,000 | 464,066,000 | -105,917,000 |
| Dec 2022 | 2,090,000 | -197,806,000 | -50,354,000 | 702,647,000 | 155,058,000 | 542,220,000 | -178,792,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
PureTech Health gets Panmure Liberum ‘buy’ on value and cash returns
2026-10-07 14:00 · Yahoo
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
2026-10-30 07:00 · Yahoo
PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
2026-10-29 11:01 · Yahoo
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
2026-10-29 11:00 · Yahoo
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
2026-10-26 07:00 · Yahoo
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
2026-10-19 06:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
2026-10-09 17:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 17:00 · Yahoo
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
2026-09-30 11:00 · Yahoo
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.